Access Biotechnology led a $140m funding round in Draig Therapeutics.

Access Biotechnology, the corporate venture arm of Access Industries, led a $140m funding round in Draig Therapeutics, a clinical-stage company aiming to transform the treatment of neuropsychiatric diseases, with participation from Canaan Partners, SR One, Sanofi Ventures, Schroders Capital, ICG and SV Health Investors. Draig was formed through a partnership between Cardiff University’s Medicines Discovery Institute and SV Health Investors and launched in 2024. SV Health Investors and ICG provided initial seed funding and built the company.